Millennium Management’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-125,000
Closed -$3.01M – 6177
2026
Q2
$3.01M Buy
+125,000
New +$3.79M ﹤0.01% 3471
2025
Q4
– Sell
-200,500
Closed -$1.45M – 6040
2025
Q3
$1.45M Buy
200,500
+160,500
+401% +$1.18M ﹤0.01% 4335
2025
Q2
$397K Buy
+40,000
New +$423K ﹤0.01% 5049
2024
Q4
– Sell
-24,100
Closed -$367K – 5983
2024
Q3
$367K Buy
+24,100
New +$119K ﹤0.01% 5064

Other funds holding CAPR

Millennium Management's CAPR Position: Q3 2026 in Review

Millennium Management increased its Capricor Therapeutics (CAPR) stake by 614% in Q3 2026, buying an estimated $15.9M and bringing the position to 1,669,083 shares worth $15.8M. The position accounts for 0.01% of the portfolio, ranked #1838.

Millennium Management first reported a position in CAPR in Q1 2015 and has held it in 24 quarters since. The position peaked at $19.7M in Q4 2025. 155 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Millennium Management held 1,669,083 shares of Capricor Therapeutics worth $15.8M as of Q3 2026.
  • Millennium Management bought 1,435,157 Capricor Therapeutics shares in Q3 2026, an estimated $15.9M.
  • Capricor Therapeutics made up 0.01% of Millennium Management's portfolio in Q3 2026, its #1838 holding.
  • Millennium Management first reported a position in Capricor Therapeutics in Q1 2015 and has held it in 24 quarters since.
  • Millennium Management's Capricor Therapeutics position peaked at $19.7M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.